Zepbound's price started at a flat $1,059 a month and now varies by dose and seller

Zepbound (tirzepatide) reached the market with a list price of $1,059 for a 28-day supply that did not change with the dose — 2.5 milligrams cost the same as 15 milligrams ^[1]. Lilly has since shifted to pricing that varies by dose and by how patients buy the drug ^[1][2].

In an announcement on Aug. 27, 2024, Lilly cut the price of the two lowest doses: $399 a month for 2.5 mg and $549 a month for 5 mg, down from the $1,059 list price ^[1]. Those prices applied only to single-dose vials sold through LillyDirect, the company's telehealth platform, and only to patients paying cash. The doses were not covered by insurance, and patients who chose them did not qualify for Lilly's discount savings program ^[1]. The same doses remained available as auto-injector pens at the higher price ^[1]. Lilly said it could charge less because vials avoid the manufacturing steps required for the pens. "These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option," Patrik Jonsson, president of Lilly USA, said in a press release ^[1].

Lilly's current pricing page lists Zepbound's list price as $499 to $1,086.37 per fill ^[2]. Direct-to-patient self-pay prices run $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg, sold as a four-count set of single-dose vials or a single-patient-use KwikPen ^[2]. Lilly defines list price as the wholesale acquisition cost, the price at which it sells to wholesalers, and says the amount patients pay at the pharmacy may differ based on their insurance plan, pharmacy charges and any discounts available ^[2].

For people with commercial drug insurance that covers Zepbound, the company says eligible patients may pay as low as $25 for a one- or three-month supply of single-dose pens. Governmental beneficiaries are excluded, eligibility is required, and Lilly states it can change or end the program at any time without notice ^[2].

Reaction to the 2024 cuts was mixed. Dr. Maria Daniela Hurtado Andrade, an endocrinologist at the Mayo Clinic in Jacksonville, Florida, said $399 for the lowest dose is still almost $5,000 a year and called it "an insurmountable cost for many racial and ethnic minorities." She added, "The majority of patients will not be able to afford the medication, still," and said limiting the discount to lower doses meant "we're only giving people a taste of hope" ^[1]. Dr. Shauna Levy, medical director of the Tulane Bariatric Center in New Orleans, called the move an "overall win" for the obesity community and said she expected Novo Nordisk, the maker of Ozempic and Wegovy, to respond ^[1].

Why it matters for patients

The advertised price of a GLP-1 is rarely the price a patient pays. For Zepbound, the total depends on the dose, whether the drug comes as a vial or a pen, whether the patient has commercial insurance, and whether they are paying cash ^[1][2]. The lowest self-pay prices are attached to the starting doses — $299 for 2.5 mg and $399 for 5 mg — while the 10 mg, 12.5 mg and 15 mg doses are each listed at $699 for self-pay patients ^[2]. Higher doses are the ones many patients stay on long term, which is the concern Hurtado Andrade raised when she noted that $399 a month for the lowest dose comes to nearly $5,000 a year ^[1].

Insurance status also splits patients into very different groups. Someone with commercial coverage may pay as little as $25, while people on government plans such as Medicare or Medicaid are excluded from that savings card program ^[2]. Cash-pay patients buying the discounted vials cannot use the savings card at all ^[1]. Some patients had turned to compounded versions of the drug, which typically come in vials and cost less, according to the reporting on the 2024 price cut ^[1]. Whether compounded tirzepatide remains available is not addressed in these sources.

What happens next

Lilly states on its pricing page that savings card eligibility and terms may be terminated, rescinded, revoked or amended at any time without notice ^[2]. The list-price figures on that page come from AnalySource as of January 1, 2026 ^[2]. Lilly and Novo Nordisk have faced political pressure over pricing; in July 2024, President Joe Biden and Sen. Bernie Sanders wrote in a USA Today op-ed that both companies "must stop ripping off Americans with high drug prices" ^[1]. Whether Zepbound's prices change again, and whether insurers expand coverage of the higher doses, has not been disclosed.